CYTOLOGY AUTOMATION

细胞学自动化

• 批准号: 3168326
• 负责人: BART BARLOGIE
• 金额: $ 14.78万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-07-01 至 1988-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3168326
• 关键词: DNA; HeLa cells; RNA; aneuploidy; antinuclear autoantibody; biomedical automation; biopsy; bone marrow exam; breast neoplasm /cancer diagnosis; cell differentiation; cell morphology; cellular oncology; computer assisted diagnosis; computer graphics /printing; cytodiagnosis; cytology; electron microscopy; flow cytometry; fluorescent dye /probe; gene expression; genetic markers; histochemistry /cytochemistry; hormone related neoplasm /cancer; human subject; immunofluorescence technique; immunoperoxidase; lung neoplasms; lymphoma; mass screening; metastasis; multiple myeloma; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer immunodiagnosis; postmortem; prostate neoplasms; single cell analysis; tissue /cell culture; tumor antigens

Several objectives are being pursued: (1) further refinement of bivariate DNA-glucocorticoid receptor (GR) analysis of potentially glucocorticoid-sensitive hematologic neoplasms including the various forms of acute leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma. These studies will be correlated with results obtained by standard radiometric tests; (2)\the bromodeoxyuridine monoclonal antibody assay will be further developed to distinguish S phase cells with varying degrees of DNA-synthetic activity, in order to examine the mechanism underlying a divergent prognostic impact of a high S phase fraction in young versus old patients with acute myeloblastic leukemia; (3)\cellular pharmacologic studies with doxorubicin and m-AMSA will be pursued using native fluorescence or dye competition methodologies, respectively. The kinetics of uptake, peak level, and retention time will be evaluated by FCM and compared with standard radioisotope technology; (4)\continuation of DNA-RNA and DS-RNA analysis in the malignant lymphomas is planned to investigate the independent role of ploidy, proliferative activity and ds-RNA for short-\and long-term prognostic in concert with standard clinical and laboratory features; and (5)\update of primary breast cancer data will be performed to determine the prognostic importance of ploidy, proliferative activity, and ER content in approximately 200 patients with regional breast cancer. Thus, this grant will continue to examine the feasibility of new probes for FCM analysis of phenotypic tumor heterogeneity and other already established probes for the diagnosis and prognosis of two particularly heterogenous malignancies, i.e., malignant lymphoma and breast cancer. (3)

正在追求几个目标：（1）进一步细化双变量 DNA-糖皮质激素受体（GR）潜在分析 糖皮质激素敏感的血液肿瘤，包括各种形式 急性白血病、慢性淋巴细胞白血病、非霍奇金淋巴瘤 多发性骨髓瘤。 这些研究将与获得的结果相关联 通过标准辐射测试； (2)\溴脱氧尿苷单克隆 将进一步开发抗体检测来区分 S 期细胞 不同程度的 DNA 合成活性，以检查 高 S 期不同预后影响的机制 年轻急性髓细胞白血病患者与老年急性髓细胞白血病患者的比例； (3)\阿霉素和m-AMSA的细胞药理学研究将 使用天然荧光或染料竞争方法进行追求， 分别。 吸收、峰值水平和保留时间的动力学将 通过 FCM 进行评估并与标准放射性同位素技术进行比较； (4)\恶性淋巴瘤中DN​​A-RNA和DS-RNA分析的继续 计划研究倍性、增殖的独立作用 活性和 ds-RNA 用于短期和长期预后 标准临床和实验室特征；和 (5)\初级乳房的更新 将进行癌症数据以确定预后的重要性 倍性、增殖活性和 ER 含量约为 200 局部乳腺癌患者。 因此，这笔赠款将继续 检验新探针用于表型肿瘤 FCM 分析的可行性 异质性和其他已经建立的诊断探针 两种特别异质性恶性肿瘤的预后，即恶性 淋巴瘤和乳腺癌。 (3)